ARISTECH CHEMICAL CORPORATION – Trademark Portfolio
Entity Type: 03
ARISTECH CHEMICAL CORPORATION holds 22 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 12 filings in this category. The portfolio also extends into Class 17 (Rubber Goods) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include ALTAIR, POLARIS, SPECTRAPAK, and ALTAIR PLUS. The owner is based in PITTSBURG, PA.
600 GRANT STREET
PITTSBURG, PA 15230
Showing of trademarks Trademarks
Trademark Classifications
ARISTECH CHEMICAL CORPORATION's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Building materials (non-metallic); non-metallic rigid pipes for building
Frequently Asked Questions
How many trademarks does ARISTECH CHEMICAL CORPORATION have?
ARISTECH CHEMICAL CORPORATION has 22 U.S. trademarks filed with the USPTO. Of these, 4 registered, 6 abandoned, 12 cancelled.
What trademark classes does ARISTECH CHEMICAL CORPORATION file in?
ARISTECH CHEMICAL CORPORATION files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 17 (Rubber Goods), Class 19 (Building Materials). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are ARISTECH CHEMICAL CORPORATION's most well-known trademarks?
ARISTECH CHEMICAL CORPORATION's registered trademark portfolio includes well-known marks such as ALTAIR, POLARIS, SPECTRAPAK, and ALTAIR PLUS. These are among 4 currently registered trademarks in the portfolio.
What is ARISTECH CHEMICAL CORPORATION's trademark registration success rate?
ARISTECH CHEMICAL CORPORATION has a 18% trademark registration rate, with 4 out of 22 resolved applications resulting in successful registration. Currently, 0 applications are pending review.